

**Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study**

Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, Pinter C, Hough D, Sanacora G, Manji H, Drevets WC.

American journal of psychiatry

2018; 175(7):620-630

**ARTICLE IDENTIFIERS**

DOI: 10.1176/appi.ajp.2018.17060720

PMID: 29656663

PMCID: not available

**JOURNAL IDENTIFIERS**

LCCN: 22024537

pISSN: 0002-953X

eISSN: 1535-7228

OCLC ID: 01480183

CONS ID: sc 78000460

US National Library of Medicine ID: 0370512

This article was identified from a query of the SafetyLit database.